Modality
Cell Therapy
MOA
TROP-2 ADC
Target
Menin
Pathway
RNA Splicing
FLFabryRSV
Development Pipeline
Preclinical
Sep 2019
→ Dec 2027
PreclinicalCurrent
NCT07891664
2,587 pts·Fabry
2019-09→2027-12·Not yet recruiting
2,587 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-093mo awayNDA· FL
2027-12-201.7y awayInterim· Fabry
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Not yet…
Catalysts
NDA
2026-07-09 · 3mo away
FL
Interim
2027-12-20 · 1.7y away
Fabry
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07891664 | Preclinical | Fabry | Not yet recr... | 2587 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Cevimavacamten | Denali | NDA/BLA | Menin | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 |